Poseida Therapeutics, Inc. (PSTX) Stock Analysis
DELISTED 2025
What happened to Poseida Therapeutics, Inc. (PSTX) stock?
Poseida Therapeutics, Inc. (PSTX) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Poseida Therapeutics, Inc. (PSTX) trades at $9.50. Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies. Their pipeline targets unmet medical needs in areas like cancer and genetic disorders. Market cap: $926M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for PSTX: PSTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSTX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PSTX: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Poseida Therapeutics, Inc. (PSTX) Healthcare & Pipeline Overview
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, pioneers cell and gene therapies for unmet medical needs. Their focus on CAR-T and gene therapy platforms positions them within the competitive biotechnology landscape, targeting diseases like prostate cancer and multiple myeloma, while collaborating with companies like Takeda Pharmaceutical.
What Is the Investment Thesis for PSTX?
Poseida Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's diverse pipeline of CAR-T and gene therapy candidates offers significant potential upside, particularly if clinical trials demonstrate efficacy and safety. Key value drivers include the advancement of P-PSMA-101 through Phase I trials for mCRPC and the progress of allogeneic CAR-T programs like P-BCMA-ALLO1 for multiple myeloma. The collaboration with Takeda Pharmaceutical provides validation and potential for future partnerships. However, the company's negative profit margin of -190.8% and gross margin of -142.3% highlight the significant financial challenges associated with drug development. Successful navigation of clinical trials, regulatory approvals, and commercialization will be critical for realizing the company's potential.
Based on FMP financials and quantitative analysis
PSTX Key Highlights
Market capitalization of $926M reflects investor expectations for Poseida's pipeline of cell and gene therapies.
- Negative profit margin of -190.8% indicates substantial ongoing investment in research and development.
- Gross margin of -142.3% reflects the high costs associated with early-stage clinical development and manufacturing.
- Beta of 0.54 suggests lower volatility compared to the overall market.
- Collaboration with Takeda Pharmaceutical validates Poseida's technology and provides potential for future revenue streams.
Who Are PSTX's Competitors?
PSTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| TBPH Theravance Biopharma, Inc. | $16.95 | -0.24% | $878M | 95 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSTX's Key Strengths?
Innovative cell and gene therapy platforms.
- Diverse pipeline of clinical-stage product candidates.
- Strategic collaboration with Takeda Pharmaceutical.
- Experienced management team.
What Are PSTX's Weaknesses?
Negative profit and gross margins.
- Reliance on clinical trial success.
- Competition from larger pharmaceutical companies.
- High cash burn rate.
What Could Drive PSTX Stock Higher?
Data readout from Phase I trial of P-PSMA-101 in mCRPC (2027).
- Initiation of Phase II trials for P-BCMA-ALLO1 in multiple myeloma (2027).
- Progress in preclinical development of P-CD19CD20-ALLO1 for B cell malignancies.
- Advancement of gene therapy programs P-OTC-101 and P-FVIII-101.
What Are the Key Risks for PSTX?
Financial-distress signal — its Altman Z-Score of 0.33 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-84.7%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures could significantly impact the company's valuation.
- Regulatory delays or rejections could delay or prevent product approvals.
- Competition from larger pharmaceutical companies with greater resources.
- High cash burn rate and need for additional financing.
- Patent disputes or challenges to intellectual property.
What Are the Growth Opportunities for PSTX?
- Advancement of P-PSMA-101: The successful completion of Phase I clinical trials for P-PSMA-101 in metastatic castrate resistant prostate cancer (mCRPC) represents a significant growth opportunity. The prostate cancer therapeutics market is substantial, with a global market size estimated at $12 billion. Positive clinical data could lead to partnerships or further investment, potentially expanding into Phase II trials by 2027.
- Development of Allogeneic CAR-T Therapies: Poseida's allogeneic CAR-T programs, such as P-BCMA-ALLO1 for multiple myeloma, offer the potential for off-the-shelf treatments, addressing limitations of autologous therapies. The market for allogeneic CAR-T therapies is projected to grow rapidly, reaching $3 billion by 2030. Successful development could position Poseida as a leader in this emerging field.
- Expansion of Gene Therapy Pipeline: The development of gene therapies like P-OTC-101 and P-FVIII-101 for genetic disorders represents another growth avenue. The gene therapy market is expected to reach $25 billion by 2028. Positive preclinical and early clinical data could attract partnerships and accelerate development.
- Strategic Collaborations: Poseida's existing collaboration with Takeda Pharmaceutical provides a foundation for future partnerships. Expanding collaborations with other pharmaceutical companies or research institutions could provide access to new technologies, funding, and market opportunities. These collaborations could lead to new therapeutic candidates and revenue streams.
- Targeting Autoimmune Diseases: Expanding the application of its CAR-T technology to autoimmune diseases, such as with P-CD19CD20-ALLO1, presents a significant growth opportunity. The autoimmune disease therapeutics market is substantial, with a global market size estimated at $60 billion. Success in this area could diversify Poseida's pipeline and address a large unmet medical need.
What Are PSTX's Competitive Advantages?
- Proprietary cell and gene therapy platforms.
- Diverse pipeline of clinical-stage product candidates.
- Strategic collaboration with Takeda Pharmaceutical.
- Expertise in CAR-T cell therapy and gene editing.
What Does PSTX Do?
Poseida Therapeutics, Inc., founded in 2014 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients facing significant unmet medical needs. The company specializes in cell and gene therapies, utilizing proprietary platforms to engineer next-generation treatments. Poseida's pipeline includes autologous and allogeneic CAR-T cell therapies targeting various cancers, as well as gene therapies for genetic disorders. Their lead product candidate, P-PSMA-101, an autologous CAR-T therapy, is currently in Phase I clinical trial for metastatic castrate resistant prostate cancer (mCRPC). Other key programs include P-BCMA-ALLO1 for relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for solid tumors. Poseida is also developing allogeneic CAR-T therapies like P-CD19CD20-ALLO1 and P-BCMACD19-ALLO1, aiming to create off-the-shelf treatments. Additionally, the company is advancing gene therapies such as P-OTC-101 and P-FVIII-101. Poseida has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited, enhancing its research and development capabilities. With a focus on innovation and a diverse pipeline, Poseida aims to transform the treatment landscape for various diseases.
What Products and Services Does PSTX Offer?
- Develop autologous and allogeneic CAR-T cell therapies for cancer treatment.
- Create gene therapies for genetic disorders.
- Conduct Phase I clinical trials for lead product candidates.
- Engineer next-generation cell and gene therapies using proprietary platforms.
- Target unmet medical needs in oncology and genetic diseases.
- Collaborate with pharmaceutical companies for research and development.
How Does PSTX Make Money?
- Develop and out-license novel therapeutics.
- Generate revenue through research collaborations and partnerships.
- Advance clinical programs to increase asset value.
- Focus on high-value targets in oncology and genetic diseases.
What Industry Does PSTX Operate In?
Poseida Therapeutics operates within the rapidly evolving biotechnology industry, specifically focusing on cell and gene therapies. The competitive landscape includes established pharmaceutical companies and numerous smaller biotech firms, all vying to develop innovative treatments for cancer, genetic disorders, and other diseases. Poseida's focus on both autologous and allogeneic CAR-T therapies, along with its gene therapy programs, positions it to capitalize on the increasing demand for personalized and off-the-shelf therapeutic options.
Who Are PSTX's Key Customers?
- Patients with metastatic castrate resistant prostate cancer (mCRPC).
- Patients with relapsed/refractory multiple myeloma.
- Patients with solid tumors, including breast and ovarian cancer.
- Pharmaceutical companies through licensing and collaboration agreements.
Forward Outlook
Wall Street analysts project Poseida Therapeutics, Inc. revenue of about $44.0M for fiscal 2026, with EPS near $-1.81.
PSTX Valuation & Market Position
With a $926M market cap, Poseida Therapeutics, Inc. sits in the small-cap segment of the market.
Key Financial Metrics
Return on equity for Poseida Therapeutics, Inc. stands at -84.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Poseida Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.33 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Poseida Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Mark J. Gergen. PSTX has traded publicly since 2020.
PSTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative cell and gene therapy platforms.
- Diverse pipeline of clinical-stage product candidates.
- Strategic collaboration with Takeda Pharmaceutical.
- Experienced management team.
Bear Case
- Negative profit and gross margins.
- Reliance on clinical trial success.
- Competition from larger pharmaceutical companies.
- High cash burn rate.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PSTX Latest News
No recent news available for PSTX.
Leadership: Mark J. Gergen
CEO
Mark J. Gergen serves as the CEO of Poseida Therapeutics, bringing extensive experience in the biopharmaceutical industry. His career includes leadership roles in various biotech companies, focusing on strategic development, commercialization, and financial management. He has a proven track record in building and scaling biotech organizations. Gergen's expertise spans across multiple therapeutic areas, including oncology and genetic diseases. He is responsible for managing 350 employees.
Track Record: Under Mark Gergen's leadership, Poseida Therapeutics has advanced multiple product candidates into clinical trials and secured a strategic collaboration with Takeda Pharmaceutical. He has overseen the expansion of the company's pipeline and the development of its proprietary cell and gene therapy platforms. His strategic decisions have positioned Poseida as a key player in the emerging field of cell and gene therapies.
What Investors Ask About Poseida Therapeutics, Inc. (PSTX) — Healthcare
What happened to Poseida Therapeutics, Inc. (PSTX) stock?
Poseida Therapeutics, Inc. (PSTX) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
Can I still buy PSTX shares?
No. PSTX stopped trading on public markets in January 2025, so the shares are not available through a broker. Anything you see quoted for PSTX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PSTX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Poseida Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Poseida Therapeutics, Inc. do?
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies to treat patients with high unmet medical needs. The company engineers innovative therapeutics using proprietary platforms, including CAR-T cell therapies for various cancers and gene therapies for genetic disorders. Poseida's business model involves advancing clinical programs, securing partnerships, and out-licensing novel therapeutics to generate revenue and improve patient outcomes.
What do analysts say about PSTX stock?
Analyst coverage of Poseida Therapeutics, Inc. reflects a cautiously optimistic outlook, acknowledging the potential of its cell and gene therapy pipeline while recognizing the inherent risks in drug development. Key valuation metrics often focus on the potential peak sales of its lead product candidates and the likelihood of clinical trial success.
What are the main risks for PSTX?
The primary risks for Poseida Therapeutics, Inc. include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. Clinical trial failures could significantly impact the company's valuation and delay or prevent product approvals. Regulatory delays or rejections could also negatively affect the company's timeline and financial prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies is inherently risky.